Looks like an exciting 2013 from the J.P. Morgan Healthcare Conference

33 of 40

John Maraganore, CEO of Alnylam Pharmaceuticals

"I think rumors of our death were highly overexaggerated," John Maraganore, CEO of Alnylam Pharmaceuticals, said this week during a meeting with us. But back in 2010, the future seemed grim for RNA interference and Alnylam ($ALNY). Swiss drug giant Roche ($RHHBY) pulled the plug on research in the field. Alnylam and other developers hadn't lived up to the hype about the gene-silencing drugs, which face delivery challenges to reach disease targets deep in the body. Yet in the last 12 months, the Cambridge, MA-based biotech's stock price has jumped 130%, and the company showed that its technology could produce potential medicines such as its lead candidate for familial amyloidotic polyneuropathy, ALN-TTR02, which could be in Phase III development later this year.